

Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients

Authors

Gregorio Barilà,¹ Angela Grassi,² Concetta Conticello,³ Roberto Mina,⁴ Chiara Marcon,^{5*} Francesca Fazio,⁶ Claudio Salvatore Cartia,⁷ Martina Tinelli,⁸ Maria Livia Del Giudice,⁹ Sofia Pilerici,^{10**} Angelo Belotti,¹¹ Anna Pascarella,¹² Mariantonietta Tafuri,¹³ Serena Rocchi,^{14,15} Katia Mancuso,^{14,15} Nicola Sgherza,¹⁶ Giuseppe Mele,¹⁷ Edoardo Scmazzon,¹ Massimo Gentile,^{18,19} Marika Porrazzo,²⁰ Norbert Pescosta,²¹ Anna Furlan,²² Massimiliano Arangio Febbo,²³ Cristina Clissa,⁸ Andrea Casson,⁴ Rossella Ribolla,¹¹ Antonio Maroccia,¹² Chiara Lisi,⁶ Enrica Antonia Martino,¹⁸ Ombretta Annibali,¹³ Gabriele Buda,⁹ Elisabetta Antonioli,¹⁰ Silvia Mangiacavalli,⁷ Alberto Tosetto,¹ Pellegrino Musto,²⁴ Francesca Gay,^{4,25} Elena Zamagni,^{14,15} Maria Teresa Petrucci,⁶ Francesco Di Raimondo,³ Francesca Patriarca⁵ and Renato Zambello²⁶

¹Hematology Unit, San Bortolo Hospital, Vicenza; ²Clinical Research Unit, Veneto Institute of Oncology, IOV-IRCCS, Padova; ³Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania; ⁴Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin; ⁵Hematology and Transplant Center Unit, Udine University Hospital, DAME, University of Udine, Udine; ⁶Division of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Universitaria Policlinico Umberto I, Sapienza University of Rome, Rome; ⁷Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia; ⁸Department of Medicine, Section of Hematology, University of Verona, Verona; ⁹Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa; ¹⁰Hematology Unit, Careggi Hospital, Florence; ¹¹Department of Hematology, ASST Spedali Civili di Brescia, Brescia; ¹²Hematology Unit, Azienda ULSS3 Serenissima, Ospedale dell'Angelo, Venezia-Mestre; ¹³Hematology and Stem Cell Transplantation Unit, Campus Bio-Medico University, Rome; ¹⁴IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna; ¹⁵Dipartimento di Scienze Mediche e Chirurgiche, Università di

Bologna, Bologna; ¹⁶Hematology and Stem Cell Transplantation Unit, AOU Consorziiale Policlinico, Bari; ¹⁷Hematology and Stem Cell Transplant Unit, Ospedale Antonio Perrino, Brindisi; ¹⁸Hematology Unit, Department of Onco-hematology, A.O. of Cosenza, Cosenza; ¹⁹Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende; ²⁰Hematology Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste; ²¹Ematologia e Centro TMO, Ospedale Centrale Bolzano, Bozen; ²²Hematology Unit, Ospedale Santa Maria di Ca' Foncello, Treviso; ²³Onco-hematology, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua; ²⁴Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine and Hematology and Stem Cell Transplantation Unit, AOU Consorziiale Policlinico, Bari; ²⁵Department of Molecular Biotechnology and Health Science, Turin and ²⁶Department of Medicine (DIMED), Hematology and Clinical Immunology Section, Padua University School of Medicine, Padua, Italy.

^{*}*Current address: Centro Immunotrasfusionale, Ospedale Santa Maria della Misericordia, ASUFC, Udine, Italy.*
^{**}*Current address: Hematology Unit, Versilia Hospital, Lido di Camaiore, Italy.*

Correspondence:
R. ZAMBELLO - r.zambello@unipd.it

<https://doi.org/10.3324/haematol.2024.286825>


Received: December 11, 2024.
Accepted: April 23, 2025.
Early view: April 30, 2025.

©2025 Ferrata Storti Foundation
Published under a CC BY-NC license 

SUPPLEMENTARY

Supplementary Figure 1: Progression Free Survival and Overall Survival in the study cohort population.


Kaplan-Meier curves showing the Progression Free Survival (PFS) (panel A) and Overall Survival (OS) (panel B) of patients who received Lenalidomide maintenance after VTD induction and autologous stem cell transplantation (ASCT).



Supplementary Figure 2: Progression Free Survival according to ISS, R-ISS, R2-ISS, LDH levels and response

Kaplan-Meier curves showing the Progression Free Survival (PFS) according to ISS (panel A), R-ISS (panel B), R2-ISS (panel C) and LDH levels (panels D).

Panel E shows the Kaplan-Meier curves regarding the PFS of patients who were in complete response before starting Lenalidomide maintenance while panel F displays the Kaplan-Meier curves of the 24-month landmark analysis of patients in complete response at 2 years from maintenance initiation. Kaplan-Meier curves were compared using the log-rank test.



Supplementary Table 1: Baseline demographics, biological and clinical characteristics of the study's patients.

Characteristic	Cohort (n=602)
Gender Male – no./total no. (%)	336/601 (55.9%)
Age at maintenance initiation, years Median [Q1;Q3] [min; max]	60[53; 65][24;74]
ISS	
I – no./total no. (%)	259/557(46.5%)
II – no./total no. (%)	177/557 (31.8%)
III – no./total no. (%)	121/557 (21.7%)
R-ISS	
I – no./total no. (%)	150/440(34.1%)
II – no./total no. (%)	244/440 (55.5%)
III – no./total no. (%)	46/440 (10.5%)
R2-ISS	
I – no./total no. (%)	116/358 (32.4%)
II – no./total no. (%)	95/358 (26.5%)
III – no./total no. (%)	116/358 (32.4%)
IV – no./total no. (%)	31/358 (8.7%)
LDH>ULN – no./total no. (%)	74/510 (14.5%)
Chromosomal abnormalities	
High risk [del(17p),t(4;14),t(14;16)] – no./total no. (%)	79/442 (17.9%)
Isolated +1q – no./total no. (%)	66/424 (15.6%)
ASCT	
1 – no./total no. (%)	392/600 (65.3%)
2 – no./total no. (%)	208/600 (34.7%)
Pre-maintenance response	
SD – no./total no. (%)	3/601 (0.5%)
PR – no./total no. (%)	76/601 (12.6%)
VGPR – no./total no. (%)	236/601 (39.3%)
CR – no./total no. (%)	188/601 (31.3%)
sCR – no./total no. (%)	98/601 (16.3%)

Percentages might not sum to 100 because of rounding.

Denominator might not be equal to 602 due to missing data.

Abbreviations. ISS: international staging system. R-ISS: revised international staging system. R2-ISS: second revision of the international staging system LDH: lactate dehydrogenase. SD: stable disease. PR: partial response. VGPR: very good partial response. CR: complete response. sCR: stringent complete response.